TESARO (NASDAQ:TSRO) had its target price lowered by investment analysts at Morgan Stanley from $165.00 to $156.00 in a report issued on Tuesday. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 124.17% from the stock’s previous close.
A number of other brokerages have also weighed in on TSRO. Robert W. Baird reaffirmed a “neutral” rating and issued a $125.00 price target on shares of TESARO in a research note on Monday, October 2nd. Zacks Investment Research lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. HC Wainwright began coverage on shares of TESARO in a research report on Thursday, October 12th. They issued a “buy” rating and a $158.00 price target for the company. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $117.00 price objective on shares of TESARO in a research note on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. TESARO has a consensus rating of “Hold” and an average price target of $152.26.
Shares of TESARO (TSRO) traded down $2.07 during trading hours on Tuesday, hitting $69.59. 1,747,500 shares of the stock were exchanged, compared to its average volume of 1,093,056. The firm has a market cap of $3,780.00, a price-to-earnings ratio of -8.26 and a beta of 1.51. TESARO has a 12 month low of $69.38 and a 12 month high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
In other news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at approximately $690,529.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 34.60% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Exane Derivatives acquired a new position in shares of TESARO during the 3rd quarter worth $106,000. Nordea Investment Management AB acquired a new position in shares of TESARO during the 2nd quarter worth $167,000. Oppenheimer Asset Management Inc. increased its stake in shares of TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares during the last quarter. Toronto Dominion Bank increased its stake in shares of TESARO by 244.6% during the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Achmea Investment Management B.V. acquired a new position in shares of TESARO during the 2nd quarter worth $234,000.
COPYRIGHT VIOLATION WARNING: “TESARO (TSRO) Price Target Cut to $156.00” was originally reported by American Banking and Market News and is the sole property of of American Banking and Market News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/tesaro-tsro-price-target-cut-to-156-00.html.
About TESARO
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
